Journal Article

The Affordable Medicines Facility-malaria (AMFm): are remote areas benefiting from the intervention?

Kyobutungi, Catherine, Hanson, Kara, Wamukoya, Marilyn, Amuasi, John, Njogu, Julius, Evance, Illah, Blay, Samuel, Thougher, Sarah, Toda, Mitsuru, Mann, Andrea, Ye, Yazoume, O’Connell, Kathryn, Goodman, Catherine, Noor, Abdisalan, Mberu, Blessing, Ren, Ruilin, Willey, Barbara, Wekesah, Frederick, Shewchuk, Tanya, Gatakaa, Hellen, Arnold, Fred

2015

Overview

Background To assess the availability, price and market share of quality-assured artemisinin-based combination therapy (QAACT) in remote areas (RAs) compared with non-remote areas (nRAs) in Kenya and Ghana at end-line of the Affordable Medicines Facility-malaria (AMFm) intervention. Methods Areas were classified by remoteness using a composite index computed from estimated travel times to three levels of service centres. The index was used to five categories of remoteness, which were then grouped into two categories of remote and non-remote areas. The number of public or private outlets with the potential to sell or distribute anti-malarial medicines, screened in nRAs and RAs, respectively, was 501 and 194 in Ghana and 9980 and 2353 in Kenya. The analysis compares RAs with nRAs in terms of availability, price and market share of QAACT in each country. Results QAACT were similarly available in RAs as nRAs in Ghana and Kenya. In both countries, there was no statistical difference in availability of QAACT with AMFm logo between RAs and nRAs in public health facilities (PHFs), while private-for-profit (PFP) outlets had lower availability in RA than in nRAs (Ghana: 66.0 vs 82.2 %, p  < 0.0001; Kenya: 44.9 vs 63.5 %, p  = <0.0001. The median price of QAACT with AMFm logo for PFP outlets in RAs (USD1.25 in Ghana and USD0.69 in Kenya) was above the recommended retail price in Ghana (US$0.95) and Kenya (US$0.46), and much higher than in nRAs for both countries. QAACT with AMFm logo represented the majority of QAACT in RAs and nRAs in Kenya and Ghana. In the PFP sector in Ghana, the market share for QAACT with AMFm logo was significantly higher in RAs than in nRAs (75.6 vs 51.4 %, p  < 0.0001). In contrast, in similar outlets in Kenya, the market share of QAACT with AMFm logo was significantly lower in RAs than in nRAs (39.4 vs 65.1 % , p  < 0.0001). Conclusion The findings indicate the AMFm programme contributed to making QAACT more available in RAs in these two countries. Therefore, the AMFm approach can inform other health interventions aiming at reaching hard-to-reach populations, particularly in the context of universal access to health interventions. However, further examination of the factors accounting for the deep penetration of the AMFm programme into RAs is needed to inform actions to improve the healthcare delivery system, particularly in RAs.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V
• Subject: Antimalarials - therapeutic use / Artemisinins - therapeutic use / Biomedical and Life Sciences / Biomedicine / Care and treatment / Comparative analysis / Cross-Sectional Studies / Development and progression / Drug Therapy, Combination - methods / Economic aspects / Entomology / Geography / Ghana / Health promotion / Health Services Accessibility / Humans / Infectious Diseases / Kenya / Lactones - therapeutic use / Malaria / Malaria - drug therapy / Microbiology / Parasitology / Patient outcomes / Public Health / Stock price indexes / Tropical Medicine / Vector-borne diseases